|
|
Intravenous
carboplatin for recurrent malignant glioma: a phase II study
Yung
WK, Mechtler L, Gleason MJ
Department
of Neuro-Oncology, University of Texas MD Anderson Cancer Center, Houston 77030
Thirty
patients with recurrent malignant glioma were treated with intravenous (IV)
carboplatin (CBDCA) every 4 weeks at a starting dose of 400 mg/m2 escalating to
450 mg/m2.
All patients had documented recurrent tumor after prior radiotherapy but had not
received prior chemotherapy.
Of 29 assessable patients, four (14%) responded to the treatment for 44, 51+,
72, and 91 weeks; 10 (34%) achieved stable disease (S); while 15 (52%) had
progressive disease (P).
The total response (responses plus S) rate was 48%, with a median time to
progression (MTP) of 26 weeks in these patients; the MTP for all 29 patients was
11 weeks.
The toxic effects were mainly hematologic, with thrombocytopenia and
granulocytopenia being mild at 400 mg/m2 and 450 mg/m2 doses.
NO neurotoxicity or renal toxicity was encountered.
These results suggest that CBCDA given at 400 mg/m2 or 450 mg/m2 every 4 weeks
is marginally active in patients with recurrent malignant gliomas.
Since hematologic toxicity is mild, a higher dose could possibly be given, and
may increase the response rate.
PMID:
1849986 [PubMed - indexed for MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1849986&dopt=Abstract |
